Table 2.

Treatment effects: polysomnographic sleep measures at baseline, pergolide crossover period (0.50 ± 0.17 mg), and follow-up (0.37 ± 0.15 mg pergolide) of 22 patients who completed the follow-up

Efficacy criteriaBaselineEnd-of-study pergolideFollow-upp Value FU vs BLp Value FU vs PGL
Values are expressed as mean ± SD.
* PLM per hour time in bed.
† PLMS arousal per hour total sleep time.
FU = follow-up; BL = baseline; PGL = pergolide at the end of the crossover period; TIB = time in bed; PLM = periodic leg movements during sleep and wakefulness.
Total sleep time, min273.6 ± 93.5372.7 ± 55.5346.2 ± 64.10.00010.0223
Sleep-onset latency, min39.2 ± 37.626.8 ± 20.321.1 ± 17.30.14840.3168
Sleep efficiency, %57.1 ± 19.077.5 ± 11.372.1 ± 13.20.00010.0392
No. of spontaneous awakenings11.3 ± 6.122.5 ± 10.522.1 ± 16.80.00070.9001
Wake time, % TIB42.9 ± 19.022.5 ± 11.327.9 ± 13.20.00010.0392
PLM381.8 ± 229.743.1 ± 48.2123.3 ± 161.60.00010.0258
PLM index*48.0 ± 28.75.4 ± 6.115.4 ± 20.20.00010.0258
PLMS arousal129.6 ± 100.113.2 ± 18.131.1 ± 64.80.00010.1989
PLMS arousal index31.8 ± 24.22.2 ± 3.35.4 ± 11.00.00010.1315
No. of PLMS awakening7.4 ± 5.92.4 ± 3.93.5 ± 5.00.00430.2644